BIO Notebook Day 3: ARM Launches Foundation To Educate Public About Gene And Cell Therapies

Alliance for Regenerative Medicine initiative seeks to explain gene and cell therapy to the general public. Also, EY's Giovannetti says strategic decisions, not tax reform, should drive deal-making; FDA's Woodcock touts benefits of new drug review office overhaul; and Siga Technologies eyes priority review voucher upon approval of Tpoxx for smallpox.

BIO International 2018 Notebook

The potential for gene and cell therapies may seem limitless and exciting, but a flip side of that story can be fear generated by the unknown. That is the issue the Alliance for Regenerative Medicine (ARM) decided to address by launching a non-profit foundation June 6 – with an announcement at the 2018 BIO International Convention in Boston – to increase the public’s awareness of and understanding about gene and cell therapy.

As a 501(c)(3) non-profit affiliated with ARM, the ARM Foundation for Cell and Gene Medicine will begin with three primary tasks on its “to-do list,” the foundation’s Chairwoman Stewart Parker told Scrip. It will launch an education program to better explain to the general public what gene/cell therapy is and is not, with initiatives including a website, public service announcements and social media campaigns

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell & Gene Therapies

More from Advanced Technologies

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By 

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.